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Uncovering the dark side of TNF
In the early 1980s, in search of the cytokine that triggers disease-
associated weight loss and lethal shock, Anthony Cerami and Bruce Beutler 
purified “cachectin.” They soon found out that their malevolent cytokine 
already had another name—tumor necrosis factor (TNF)—and was being 
lauded as a potential antitumor agent.
The bright side
Although TNF itself was not discovered 
until the 1970s, a physician named 
William Coley first noted the phenom-
enon of tumor necrosis at the turn of 
the 20th century. The tumors of some 
of his cancer patients shrank after they 
had acquired streptococcal infections (1). 
But the inherent dangers of injecting 
humans with a toxic soup of bacterial 
endotoxins prevented Coley’s observa-
tion from being converted into an anti-
tumor therapy. Researchers, however, 
hoped to separate the tumor-blasting 
factor from the toxic mess. Lloyd Old 
and his team at the Memorial Sloan 
Kettering Cancer Center (New York, 
NY) finally zeroed in on serum TNF 
from bacterium-primed, endotoxin-
challenged mice in 1975 (2).
TNF was immediately included 
with the likes of interferon-γ, IL-2, and 
monoclonal antibodies as the next best 
hope in cancer treatment. By the mid-
1980s, it was being tested on cancer 
patients all over the world. The results, 
however, were lackluster. TNF therapy 
not only failed to shrink tumors but also 
caused side effects. And just across the 
street from Sloan Kettering, a group 
from Rockefeller University headed by 
Anthony Cerami would soon publish 
data that would put a further damper on 
the TNF-as-cure idea.
The “wasting” connection
Cerami had not started out trying to 
expose TNF’s seamier side. His main 
interest was in understanding the basis 
of cachexia—the weight loss associated 
with many chronic diseases, such as 
cancer and tuberculosis. In the 1970s, 
while testing drugs designed to rid cattle 
of the parasite Trypanosoma, Cerami 
noticed that the animals continued to 
waste away even though the parasites 
were dying off. The continued weight 
loss was not drug induced, as parasite-
infested antelopes also responded to the 
drug but showed no further wasting. 
Cachexia, Cerami surmised, might be 
due to a host factor that was meant to 
fight the infection but became a threat 
when produced in amounts that over-
whelmed the body.
Cerami soon found a reliable bio-
chemical read-out for cachexia: lipaemia, 
the accumulation of lipids in the blood 
due to the suppression of a fat-metaboliz-
ing enzyme (3). The hypothetical host 
factor, Cerami realized, might be sup-
pressing this enzyme, lipoprotein lipase 
(LPL), thus triggering a fat storage 
problem and cachexia. He and a post-
doctoral associate, Masanobu Kawakami, 
tested this hypothesis in a mouse model 
of endotoxin-induced cachexia. Mice 
that were genetically susceptible to endo-
toxin had deficient LPL activity after an 
injection of bacterial lipopolysaccharide 
(LPS), whereas endotoxin-resistant 
mice had normal LPL activity. Serum 
from LPS-treated sensitive mice trig-
gered LPL suppression in normally 
resistant mice, suggesting the presence 
of the cachexia-inducing host factor 
in the serum.
A cytokine by any other name
The task of purifying this mystery 
protein was taken up by Bruce Beutler, 
another of Cerami’s post-doctoral asso-
ciate. The team had previously found 
that a macrophage cell line produced 
copious amounts of the LPL-suppress-
ing factor when stimulated by endo-
toxin (4). The macrophage prep was 
also a better starting point for protein 
purification compared with the messy 
mouse serum. Beutler then took a year 
to purify the protein, which the team 
named “cachectin.” They published 
their discoveries in the Journal of Experi-
mental Medicine (5, 6).
Beutler sequenced cachectin and 
initially thought he was dealing with a 
unique protein. The team’s collabora-
tors at the Scripps Institute (La Jolla, 
CA), however, found that cachectin 
shared the same biological activity 
with TNF. A comparison of cachectin’s 
sequence with that of the newly se-
quenced human TNF solidified the 
link. The team added this later discov-
ery as a footnote to their already-
accepted paper (5).
Therapy becomes therapeutic target
The identification of cachectin as the 
benign cytokine TNF created a furor in 
the field, especially as the other biological 
activities of cachectin mimicked the 
side effects seen in the TNF-treated 
cancer patients. “Everyone else was 
advocating for TNF to be given to 
patients,” says Cerami. “We wanted to 
get rid of it”. His team later found that 
blocking TNF activity using antibodies 
reduced infection-induced inflamma-
tion and endotoxin-induced lethality (7). 
Today, anti-TNF drugs are successfully 
used in the treatment of inflammatory 
diseases such as rheumatoid arthritis 
and psoriasis.
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